Showing results (61-70 of 127) with videos related to
Sort By:
Pageof 13
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2011
Cigarette smoking increases copy number alterations in nonsmall-cell lung cancerYen-Tsung Huang, Xihong Lin, Yan Liu, et al.Journal of Cellular and Molecular Medicine|December 2, 2008
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinomaJustine A Barletta, Sven Perner, A John Iafrate, et al.The Journal of Pathology|September 18, 2020
Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesotheliomaAssunta De Rienzo, Lucian R Chirieac, Yin P Hung, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western populationScott J Rodig, Mari Mino-Kenudson, Sanja Dacic, et al.Journal of Surgical Oncology|June 3, 2015
Image-guided video assisted thoracoscopic surgery (iVATS) - phase I-II clinical trialRitu R Gill, Yifan Zheng, Julianne S Barlow, et al.Cancer Research|October 15, 2009
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokersLynette M Sholl, Beow Y Yeap, A John Iafrate, et al.Oral Oncology|July 4, 2012
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerMissak Haigentz, Mimi Kim, Catherine Sarta, et al.The Journal of Clinical Investigation|January 27, 2007
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomasDanan Li, Hongbin Ji, Sara Zaghlul, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatinGeoffrey D Girnun, Liang Chen, Jessica Silvaggi, et al.British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.Pageof 13